Literature DB >> 19684396

Urinary trypsin inhibitors afford cardioprotective effects through activation of PI3K-Akt and ERK signal transduction and inhibition of p38 MAPK and JNK.

Seok J Kim1, Kyung Y Yoo, Cheol W Jeong, Woong M Kim, Hyung K Lee, Hong B Bae, Sang H Kwak, Mei Li, JongUn Lee.   

Abstract

BACKGROUND: We determined the effect of urinary trypsin inhibitors (UTI) in regional myocardial ischemia/reperfusion (I/R) injury and its underlying mechanisms involving the role of prosurvival kinases such as phosphatidylinositol-3-OH kinases (PI3K)-Akt and extracellular signal-regulated kinases (ERK 1/2) and apoptotic kinases such as p38 and JNK.
METHODS: The rats were anesthetized and subjected to an I/R insult consisting of 30-min left anterior descending coronary artery (LAD) occlusion followed by reperfusion. Infarct size was measured after 120 min of reperfusion. UTI was given alone or along with wortmannin (inhibitor of PI3K) or PD098059 (inhibitor of ERK1/2) before LAD occlusion. The phosphorylation of Akt, ERK1/2, p38 and JNK was determined by immunoblotting after 5 min of reperfusion. UTI was administered 10 min before LAD occlusion, and wortmannin and PD098059 were administered 20 min before LAD occlusion.
RESULTS: UTI significantly reduced the infarct size compared with the control. Wortmannin or PD098059 alone did not affect the infarct size, but they abolished the UTI-induced cardioprotective effect. UTI significantly reduced the phosphorylation of p38 and JNK, while it enhanced that of Akt and ERK1/2.
CONCLUSIONS: UTI has a protective effect against regional myocardial I/R injury through activation of survival kinases PI3K-Akt and ERK1/2 and attenuation of p38 and JNK.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19684396     DOI: 10.1159/000234321

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  8 in total

1.  Urinary trypsin inhibitor attenuates lipopolysaccharide-induced acute lung injury by blocking the activation of p38 mitogen-activated protein kinase.

Authors:  Xinying Zhang; Fengqin Liu; Haiyan Liu; Hongxia Cheng; Wei Wang; Qiang Wen; Yulin Wang
Journal:  Inflamm Res       Date:  2011-01-19       Impact factor: 4.575

2.  Urinary trypsin inhibitor: miraculous medicine in many surgical situations?

Authors:  Jong In Han
Journal:  Korean J Anesthesiol       Date:  2010-04-28

3.  Urinary trypsin inhibitor attenuates liver enzyme elevation after liver resection.

Authors:  Cheol-Won Jeong; Cha-Sup Lee; Seong-Heon Lee; Hye Jin Jeung; Sang-Hyun Kwak
Journal:  Korean J Anesthesiol       Date:  2012-08-14

Review 4.  Effect of Ulinastatin in the Treatment of Postperative Cognitive Dysfunction: Review of Current Literature.

Authors:  Zheng-Tao Lv; Jun-Ming Huang; Jin-Ming Zhang; Jia-Ming Zhang; Jin-Feng Guo; An-Min Chen
Journal:  Biomed Res Int       Date:  2016-08-14       Impact factor: 3.411

5.  Ulinastatin Ameliorates Pulmonary Capillary Endothelial Permeability Induced by Sepsis Through Protection of Tight Junctions via Inhibition of TNF-α and Related Pathways.

Authors:  Ming Fang; Wen-Hong Zhong; Wen-Liang Song; Yi-Yu Deng; Duo-Meng Yang; Bin Xiong; Hong-Ke Zeng; Hua-Dong Wang
Journal:  Front Pharmacol       Date:  2018-08-13       Impact factor: 5.810

6.  Protective effect of sauchinone against regional myocardial ischemia/reperfusion injury: inhibition of p38 MAPK and JNK death signaling pathways.

Authors:  Seok Jai Kim; Cheol Won Jeong; Hong Beom Bae; Sang Hyun Kwak; Jong-Keun Son; Chang-Seob Seo; Hyun-Jung Lee; JongUn Lee; Kyung Yeon Yoo
Journal:  J Korean Med Sci       Date:  2012-04-25       Impact factor: 2.153

7.  Beneficial effects of ulinastatin on gut barrier function in sepsis.

Authors:  Longyuan Jiang; Lianhong Yang; Meng Zhang; Xiangshao Fang; Zitong Huang; Zhengfei Yang; Tianen Zhou
Journal:  Indian J Med Res       Date:  2013-12       Impact factor: 2.375

8.  Ulinastatin attenuates diabetes-induced cardiac dysfunction by the inhibition of inflammation and apoptosis.

Authors:  Wen-Ke Wang; Qing-Hua Lu; Xin Wang; Ben Wang; Juan Wang; Hui-Ping Gong; Lin Wang; Hao Li; Yi-Meng Du
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.